Review of the Efficacy and Safety of Switching to Iglarlixi Treatment in T2DM Management with Various Glycemic Control Regimens

Speaker(s)

ABSTRACT WITHDRAWN

OBJECTIVES: iGlarLixi is a fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide. This review aims to summarize the effectiveness and safety of switching to the innovative drug iGlarLixi in the treatment of T2DM patients following various glycemic control strategies

METHODS: This review examines RCTs investigating iGlarLixi in patients with T2DM to synthesize the effectiveness and safety of iGlarLixi treatment.

RESULTS: The LixiLan-L study included T2DM patients who had received basal insulin-oral antidiabetic therapy regimens. The study found that the iGlarLixi group had a lower HbA1c level( -1.1%, -0.6% in iGlar group, p < 0.0001). A significantly higher proportion of patients in the iGlarLixi group (55.0%) achieved the HbA1c target < 7.0% compared to the iGlar group (30.0%). Additionally, the iGlarLixi group experienced a mean weight reduction (-0.7 kg), whereas the iGlar group showed weight gain (+0.7 kg; p < 0.0001). The LixiLan-G study found that the group of patients switching from GLP-1 RAs to iGlarLixi had a higher proportion of patients reaching the HbA1c < 7.0% target without documented symptomatic hypoglycemia (< 70 mg/dL; 43% in the iGlarLixi group vs. 25% in the GLP-1 RAs group). The LixiLan-O study enrolled T2DM patients treated with OADs. It found that the HbA1c level in the iGlarLixi group was 6.5% (LS mean change -1.63%), compared to 6.8% (LS mean change -1.34%) in the iGlar group and 7.3% (LS mean change -0.85%) in the Lixi group.

CONCLUSIONS: For T2DM patients, transitioning from various antidiabetic treatments to iGlarLixi has shown clinical benefits in glycemic control, weight management, and safety.

Code

CO67

Topic

Clinical Outcomes

Topic Subcategory

Clinical Outcomes Assessment

Disease

Diabetes/Endocrine/Metabolic Disorders (including obesity), Drugs